Who founded Perfuse Therapeutics?

Perfuse Therapeutics was founded by Sevgi Gurkan, MD in 2018.

Who are Perfuse Therapeutics's investors?

Perfuse Therapeutics's investors include OrbiMed, Access Biotechnology, Catalio Capital Management, LP, Hatteras Venture Partners, LAV, Lilly Asia Ventures, Hatteras.

How much funding has Perfuse Therapeutics raised?

Perfuse Therapeutics has disclosed $11M raised across 2 rounds.

Where is Perfuse Therapeutics headquartered?

Perfuse Therapeutics is headquartered in San Francisco, US.

Perfuse Therapeutics

San Francisco, US · Founded 2018 · Delaware corporation · 9 employees on LinkedIn · 7 known investors

Find your way into Perfuse Therapeutics

720 people in our graph share verified history with the Perfuse Therapeutics team — schools, employers, funds. One of them is your warm intro.

Paul Kwanunlockedknows Sevgi Gurkan · together at Stanford University (overlapped)

×6knows the team · via University of Southern California

×3knows the team · via Stanford University

×2knows the team · via Icahn School of Medicine at Mount Sinai

Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms. The company focuses on advancing therapeutic programs from preclinical development through clinical stages.

Biotech Healthtech Medical Devices

Founders & leadership

Perfuse Therapeutics was founded in 2018 by Sevgi Gurkan, MD.

Sevgi Gurkan, MD in 𝕏Founder, Chief Executive Officer, and Member of the Board of DirectorsVenture Partner at OrbiMed

Board

Christy ShafferBoard director

Chau KhuonginBoard directorPartner at OrbiMed

Sevgi Gurkan in 𝕏Founder, President and CEOVenture Partner at OrbiMed

Investors · 7

OrbiMed✓ verifiedNew York · $1M – $75Mvia Chau Khuong · board

Access BiotechnologyNew York City

Catalio Capital Management, LPNew York

Hatteras Venture PartnersResearch Triangle · $500K – $4M

LAVHong Kong · $5M – $15M

Lilly Asia VenturesHong Kongvia Hongbo Lu · board

HatterasreportedRaleigh

Reported raises · per SEC filings

Form D private placements

$11M disclosed across 2 rounds · 2019–2020

▶$9MraisedJul 2020 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Hongbo LuDirector
Christy ShafferDirector
Chau KhuongDirector
Sevgi GurkanExecutive Officer, Director, Promoter
Dan BeckerDirector
Jerry CagleDirector

Offering amount: $39M
Amount sold: $9M
First sale: Jul 2020
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2MraisedApr 2019 · 6 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Christy ShafferDirector
Chau KhuongDirector
Sevgi GurkanExecutive Officer, Director, Promoter

Offering amount: $4M
Amount sold: $2M
First sale: Mar 2019
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Ois8 shared keywordsOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.

Companies competing with Perfuse Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Bayer acquires Hatteras-backed Perfuse Therapeutics for up to $2.45B - Triangle Business Journalbizjournals.com · Jun 2026

Bayer dips toes back into pharma M&A to buy Perfuse Therapeuticsendpoints.news · May 2026

Frequently asked questions

What does Perfuse Therapeutics do?: Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms. The company focuses on advancing therapeutic programs from preclinical development through clinical stages.
Who founded Perfuse Therapeutics?: Perfuse Therapeutics was founded by Sevgi Gurkan, MD in 2018.
Who are Perfuse Therapeutics's investors?: Perfuse Therapeutics's investors include OrbiMed, Access Biotechnology, Catalio Capital Management, LP, Hatteras Venture Partners, LAV, Lilly Asia Ventures, Hatteras.
How much funding has Perfuse Therapeutics raised?: Perfuse Therapeutics has disclosed $11M raised across 2 rounds.
Where is Perfuse Therapeutics headquartered?: Perfuse Therapeutics is headquartered in San Francisco, US.